

Table 1: Patient characteristics. Data are presented as mean \pm standard deviation (SD), or number of participants (% of participants).

Parameter	n (%)
Age, years	67 \pm 12
Male gender	99 (52.1)
Ethnicity	
New Zealand European	76 (40.0)
Māori	35 (18.4)
Pacific peoples	35 (18.4)
Asian	24 (12.6)
Other ethnicity	20 (10.6)
Domicile hospital	
Auckland	61 (32.1)
Counties Manukau	86 (45.3)
Waitematā	43 (22.6)
Performance status (ECOG)	
Mean	1.44 \pm 1.1
<2	91 (60.5)
\geq 2	75 (39.5)
Diagnosis	
Biliary cancer	16 (8.4)
Duodenal cancer	18 (9.5)
Gastric cancer	74 (38.9)
Metastatic disease	19 (10)
Neuroendocrine tumour (NET)	6 (3.2)
Pancreatic cancer	57 (30)
Nature of obstruction	
Intrinsic	127 (66.8)
Extrinsic	63 (33.2)
Systemic disease	
Peritoneal infiltration	52 (27.4)
Ascites	33 (17.4)

Table 1 (continued): Patient characteristics. Data are presented as mean ± standard deviation (SD), or number of participants (% of participants).

Systemic treatment	
Chemotherapy	88 (46.3)
Radiotherapy	13 (6.8)

ECOG = Eastern Cooperative Oncology Group score.

Table 2: Patient outcomes after stent placement. Data are presented as mean ± standard deviation (SD), median (interquartile range [IQR]) and/or number of participants (% of participants).

Outcomes	n (%)
Technical success	186 (97.9)
Clinical success	156 (83.9)
Symptom scores	
Pre-GOOS	0.20±0.57
Post-GOOS	2.03±0.84
Type of SEMS	
Fully covered	30 (16.1)
Partially covered	20 (10.8)
Uncovered	136 (73.1)
Location of proximal stent flange	
Gastric	134 (72)
Duodenal	52 (28)

GOOS = gastric outlet obstruction symptom score; SEMS = self-expanding metal stent.

Table 3: Adverse events, reintervention and survival after stent placement. Data are presented as mean \pm standard deviation (SD), median (interquartile range [IQR]) and/or number of participants (% of participants).

Parameter	n (%)
Adverse events	
Any adverse event	82 (44.1)
Stent dysfunction	66 (35.5)
Perforation	6 (3.2)
Migration	15 (8.1)
Occlusion	45 (24.2)
Biliary obstruction	28 (15.1)
Death within 7 days	6 (3.2)
Aspiration pneumonia	2 (1.1)
GI bleeding	1 (0.5)
Disease progression	1 (0.5)
Other	2 (1.1)
Reintervention	
Participants having reintervention for GOO	60 (32.3)
Reintervention events	71
Dilatation	13 (7.0)
Repeat stent	47 (25.3)
Other endoscopic intervention ^a	6 (3.2)
Surgery	5 (2.7)
Mean reinterventions per participant	0.32 \pm 0.47
Stent patency time, days	67 \pm 76
Survival	
Post-stent survival, days	95 (37–197)
Days in hospital after stenting	4 (2–7)

^a Includes placement of nasojejun tube (4), endoscopic stent clearance (1), and treatment of tumour in growth (1).
GI = gastrointestinal bleeding; GOO = gastric outlet obstruction.

Table 4: Univariate analysis of stent dysfunction for grouped cohorts.

Variable		Stent dysfunction (%)	OR	95% CI	P-value
Age	<70 years	48 (42.9)	2.33	1.22–4.47	0.01
	≥70 years	18 (24.3)			
Gender	Male	41 (42.7)	1.94	1.05–3.58	0.05
	Female	25 (27.8)			
Ethnicity	Māori	18 (51.4)	2.27	1.08–4.79	0.03
	Non-Māori	48 (31.8)			
Performance status	ECOG <2	41 (45.6)	2.03	1.05–3.92	0.03
	ECOG ≥2	21 (29.2)			
Diagnosis	Biliary cancer	2 (12.5)	0.24	0.05–1.08	0.06
	Duodenal cancer	9 (52.9)	2.21	0.81–6.04	0.18
	Gastric cancer	38 (52.1)	3.30	1.76–6.17	<0.001
	Metastatic disease	5 (26.3)	0.62	0.21–1.81	0.46
	Neuroendocrine tumour	1 (16.7)	0.35	0.04–3.09	0.43
	Pancreatic cancer	11 (20)	0.35	0.16–0.73	0.004
Chemotherapy	Yes	35 (40.7)	1.53	0.84–2.79	0.22
	No	31 (31)			
Nature of obstruction	Intrinsic	53 (42.7)	2.81	1.39–5.71	0.004
	Extrinsic	13 (21)			
Peritoneal disease	Yes	21 (41.2)	1.4	0.72–2.72	0.39
	No	45 (33.3)			
Ascites	Yes	13 (41.9)	1.39	0.63–3.05	0.42
	No	53 (34.2)			
Proximal stent location	Gastric	53 (39.6)	1.96	0.96–4.02	0.09
	Duodenal	13 (25)			
Stent type	Covered/partially covered	31 (62)	4.71	2.37–9.37	<0.001

OR = odds ratio; CI = confidence interval; ECOG = Eastern Cooperative Oncology Group score.

Table 5: Multivariate logistic regression analysis for stent dysfunction within grouped cohorts.

Variable		Univariate p-value	OR	95% CI	P-value
Age	<70 years	0.01	1.64	0.73–3.72	0.23
	≥70 years				
Gender	Male	0.05	1.49	0.71–3.14	0.29
	Female				
Ethnicity	Māori	0.03	0.60	0.24–1.50	0.28
	Non- Māori				
Performance status	ECOG <2	0.03	2.32	1.08–4.99	0.03
	ECOG ≥2				
Diagnosis	Biliary cancer	0.06	0.32	0.05–1.97	0.22
	Duodenal cancer	0.18			
	Gastric cancer	<0.001	1.81	0.67–4.88	0.24
	Metastatic disease	0.46			
	Neuroendocrine tumour	0.43			
	Pancreatic cancer	0.004	0.58	0.20–.67	0.31
Chemotherapy	Yes	0.22			
	No				
Nature of obstruction	Intrinsic	0.004	0.92	0.32–2.65	0.88
	Extrinsic				
Peritoneal disease	Yes	0.39			
	No				
Ascites	Yes	0.42			
	No				
Proximal stent location	Gastric	0.09			
	Duodenal				
Stent type	Covered/partially covered	<0.001	3.06	1.35–6.95	0.008
	Uncovered				

OR = odds ratio; CI = confidence interval; ECOG = Eastern Cooperative Oncology Group score.

Table 6: Univariate and multivariate Cox regression analysis of mortality outcomes.

Variable		Death (%)	P-value	HR	95% CI	P-value
Age	<70 years	100 (83.3)	0.14	1.47	1.03–2.09	0.03
	≥70 years	71 (91.0)				
Gender	Male	87 (86.1)	0.92			
	Female	84 (86.6)				
Ethnicity	Māori	33 (94.3)	0.13			
	Non- Māori	138 (84.7)				
Performance status	ECOG <2	79 (80.6)	0.04			
	ECOG ≥2	68 (91.9)				
Diagnosis	Biliary cancer	2 (12.5)	0.89			
	Duodenal cancer	9 (52.9)	0.81			
	Gastric cancer	36 (49.3)	0.68			
	Metastatic disease	5 (26.3)	0.68			
	Neuroendocrine tumour	6 (100)	0.60			
	Pancreatic cancer	52 (94.5)	0.04	0.96	0.61–1.51	0.86
Chemotherapy	Yes	73 (84.9)	0.60			
	No	98 (87.5)				
Nature of obstruction	Intrinsic	111 (83.5)	0.09	0.64	0.41–0.99	0.05
	Extrinsic	60 (92.3)				
Peritoneal disease	Yes	46 (90.2)	0.36			
	No	125 (85.0)				
Ascites	Yes	32 (100)	0.01	2.23	1.39–3.58	<0.001
	No	139 (83.7)				
Proximal stent location	Gastric	122 (84.7)	0.27			
	Duodenal	49 (90.7)				
Stent type	Covered/partially covered	45 (76.3)	0.012	1.45	0.98–2.14	0.06
	Uncovered	126 (90.7)				

HR = hazard ratio; CI = confidence interval.